Incorporated on December 31st of last year, Predictus has developed a companion diagnostic for a class of oncology drugs called topoisomerase 1 (topo1) inhibitors. Meant to address the low response rates of topo1 inhibitor therapy patients, Predictus’ diagnostic will save valuable time for cancer patients and provide a powerful decision tool for physicians. Dr. Ajit Bharti, co-founder of Predictus, has spent the past ten years studying the topo1 enzyme pathway and Dr. Jeff Elton has over twenty years of experience in the pharmeceutical industy. The Office of Technology Development recently awarded Predictus with the BU Launch Award.

For more information, contact April Effort at (aeffort@bu.edu).